RLAY Q2 2022 Earnings — Relay Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RLAYRelay Therapeutics, Inc.

$2B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$365,000-56.8% YoY

Gross Profit

-$60M-16478.4% margin

Operating Income

-$78M-21318.1% margin

Net Income

-$77M-21037.8% margin

EPS (Diluted)

$-0.71

QoQ Revenue Growth

-12.9%

Cash Flow

Operating Cash Flow

-$57M

Free Cash Flow

-$59M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$889M

Total Liabilities

$110M

Stockholders' Equity

$780M

Cash & Equivalents

$108M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$365,000	$844,000	-56.8%
Gross Profit	-$60M	-$44M	-35.8%
Operating Income	-$78M	-$194M	+59.8%
Net Income	-$77M	-$193M	+60.3%

Revenue Segments

License

$300,000100%